Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics

Recognition

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Schrödinger, Inc. (Nasdaq: SDGR) announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital.

In connection with the transaction, Schrödinger contributed two early-stage small molecule programs (SDGR-4594 and SDGR-8139) and, in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora will partner with Schrödinger’s drug discovery experts and leverage Schrödinger’s computational platform at scale to further advance these programs to clinical candidates.

WilmerHale advised Schrödinger on the transaction.

The WilmerHale venture financing team consisted of Cynthia Mazareas, Scott Lunin, Andrea Sorrentino, Arpi Youssoufian and Madeline Gatto, and the WilmerHale technology licensing team consisted of Judith Hasko and Helen Park. Tax advice was provided by William Caporizzo and Meghan Walsh, and real estate advice was provided by Douglas Burton and Benjamin Unger.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel